texte alternatif                                    

    List of publications of Mattia Rediti


      Peer-reviewed journal articles (10)
  1. 1. Fernandez-Martinez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K. K., Venet, D., Rashid, N. N., Spears, P. P., Islam, M. N., El-abed, S., Bliss, J. M., Lambertini, M. M. P. M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. P., Swain, S. S., Sotiriou, C., Perou, C. C., & Carey, L. L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA oncology. doi:10.1001/jamaoncol.2023.7304
  2. 2. Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
  3. 3. Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-1267
  4. 4. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  5. 5. Fimereli, D., Venet, D., Rediti, M., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Marchio, C., Bertucci, F., Mariani, O., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Van den Eynden, G., Salgado, R., Biganzoli, E., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., Brown, D. N., Rothé, F., & Sotiriou, C. (2022). Timing evolution of lobular breast cancer through phylogenetic analysis. EBioMedicine, 82, 104169. doi:10.1016/j.ebiom.2022.104169
  6. 6. Rothé, F., Venet, D., Peeters, D., Rouas, G., Rediti, M., Smeets, D., Dupont, F., Campbell, P., Lambrechts, D., Dirix, L. Y., Sotiriou, C., & Ignatiadis, M. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ breast cancer, 8(1), 79. doi:10.1038/s41523-022-00445-7
  7. 7. Venet, D., Rediti, M., Maetens, M. M., Fumagalli, D., Brown, D. N., Majjaj, S., Salgado, R., Pusztai, L., Harbeck, N., El-Abed, S., Wang, Y., Saura, C., Gomez, H., Semiglazov, V. F., de Azambuja, E., Huober, J., Nuciforo, P. G., Di Cosimo, S., Piccart-Gebhart, M., Loi, S., Rothé, F., & Sotiriou, C. (2021). Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial. Clinical cancer research, 27(20), 5607-5618. doi:10.1158/1078-0432.CCR-21-1317
  8. 8. Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021). HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel), 13(11). doi:10.3390/cancers13112824
  9. 9. Incorvaia, L., Fanale, D., Badalamenti, G., Porta, C., Olive, D., De Luca, I., Brando, C., Rizzo, M., Messina, C., Rediti, M., Russo, A., Bazan, V., & Iovanna, J.-L. (2020). Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology, 9(1), 1832348. doi:10.1080/2162402X.2020.1832348
  10. 10. Rescigno, P., Dolling, D., Conteduca, V., Rediti, M., Bianchini, D., Lolli, C., Ong, M., Li, H., Omlin, A., Schmid, S., Caffo, O., Zivi, A., Pezaro, C. C., Morley, C., Olmos, D., Romero-Laorden, N., Castro, E., Saez, M. I., Mehra, N., Smeenk, S., Sideris, S., Gil, T., Banks, P., Sandhu, S. S., Sternberg, C. N., De Giorgi, U., & De Bono, J. S. (2019). Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European Urology Oncology. doi:10.1016/j.euo.2019.06.008
    11.   Theses and master's dissertations (1)
  11. 1. Rediti, M. (2023). Integrative multi-omic analysis: towards treatment de-escalation for early stage HER2-positive breast cancer (Unpublished doctoral dissertation). Université libre de Bruxelles, Faculté de Médecine – Sciences médicales, Bruxelles.